

TO THE EDITOR:

A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome

Ekin Güney,^{1,*} Calixto-Hope G. Lucas,^{1,*} Zhongxia Qi,² Jingwei Yu,² Ruth Zhang,¹ Robert S. Ohgami,^{1,3} James L. Rubenstein,⁴ Daniel R. Boué,⁵ Kristian Schafernak,⁶ Gerald B. Wertheim,⁷ Sonika Dahiya,⁸ Lisa Giulino-Roth,^{9,10} Andishe Attarbaschi,¹¹ Matthew J. Barth,¹² Shalin Kothari,¹³ Oussama Abla,¹⁴ Adam L. Cohen,¹⁵⁻¹⁷ Joe S. Mendez,¹⁸ Andrew Bollen,¹ Arie Perry,¹ Tarik Tihan,¹ Melike Pekmezci,^{1,3} David A. Solomon,^{1,3} and Kwun Wah Wen^{1,3}

¹Department of Pathology, ²Department of Laboratory Medicine, ³Helen Diller Family Comprehensive Cancer Center, and ⁴Department of Medicine, University of California, San Francisco, CA; ⁵Department of Laboratory Medicine and Pathology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH; ⁶Department of Laboratory Medicine and Pathology, Phoenix's Children Hospital, Phoenix, AZ; ⁷Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA; ⁸Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; ⁹Department of Pediatrics, and ¹⁰Department of Medicine, Weill Cornell Medicine, New York, NY; ¹¹Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; ¹²Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY; ¹³Section of Hematology, Yale University, New Haven, CT; ¹⁴Division of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada; ¹⁵Department of Internal Medicine, and ¹⁶Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT; ¹⁷Inova Schar Cancer Institute, Fairfax, VA; and ¹⁸Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Primary central nervous system (CNS) lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma with CNS confinement; large B-cell lymphoma (LBCL) accounts for most PCNSL. The median age for PCNSL-LBCL is 66 years, with occurrence in younger adults and pediatric cases being uncommon.¹ Although immunodeficient children have an increased risk of developing PCNSL, most cases of pediatric PCNSL in the past few decades have been reported in immunocompetent individuals. Previous studies have reported that the prognosis for PCNSL-LBCL is better in pediatric and younger adults than in older adults who have a median survival of <3 years.^{2,3} Aberrant constitutive activation of the NF- κ B signaling pathway is a hallmark of PCNSL-LBCL in adults and is characterized by frequent *MYD88* mutation, *CD79B* mutation, *PRDM1* mutation/deletion, *CDKN2A* biallelic deletion, and HLA gene cluster deletion.⁴⁻⁹ However, the molecular pathogenesis of PCNSL-LBCL in children and young adults is largely unknown and may be different from that in older adults, helping to explain the divergent clinical outcomes.

This multi-institutional study was conducted to investigate the molecular characteristics of pediatric and young-adult PCNSL-LBCL and define associations with clinical outcomes and pathologic features. The cohort consisted of 12 patients <40 years of age without known immunodeficiency, including 6 males and 6 females with median age at diagnosis of 17 years (range, 7-38 years). All patients were confirmed to have primary CNS confinement without systemic involvement based on staging positron-emission tomography/computed tomography and bone marrow biopsy. All patients were treated with a combination of dexamethasone, methotrexate, and rituximab, together with various accompanying agents (supplemental Tables 1-2). Tumors were uniformly composed of dense aggregates of large lymphoid cells with perivascular and parenchymal involvement, were Epstein-Barr virus (EBV) negative, and had diffuse strong immunoreactivity for B-cell markers (CD20 and PAX5). No *BCL2* rearrangement and no *MYC* amplification or rearrangement were present (supplemental Tables 3-4). No appreciable differences in cytology or growth pattern were identifiable between these pediatric and young-adult patients with PCNSL-LBCL compared with their older adult counterparts. The Institutional Review Board, Human Research Protection Program Committee at the University of California San Francisco approved this study (CHR 18-25787), which was conducted in accordance with the Declaration of Helsinki.

Submitted 25 August 2021; accepted 3 February 2022; prepublished online on *Blood Advances* First Edition 14 February 2022; final version published online 23 May 2022. DOI 10.1182/bloodadvances.2021006018.

*E.G. and C.-H.G.L. contributed equally to this study.

The full clinical, pathologic, and molecular data are available in the supplemental data available with the online version of this article. For further original data, please contact kwun.wen@ucsf.edu.

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.




Figure 1. Genomic analysis identifies a unique pediatric subtype of EBV-negative primary CNS large B-cell lymphoma. Clinical, histologic, and genetic features of the 12 pediatric and young-adult patients with PCNS-LBCL, alongside 6 conventional cases of PCNS-LBCL occurring in older adults. Categorization into pediatric- and adult-type tumor groups was performed according to recurrent molecular alterations involving *MYD88*, *PRDM1*, *CDKN2A/B*, HLA gene cluster, *NFKBIE*, *GNA13*, and *TP53*.

Targeted next-generation DNA sequencing and genome-wide copy number analysis were performed on the 12 tumors, as well as 6 conventional PCNS-LBCL from older adult patients (supplemental Methods). Based on the molecular signatures, 2 distinct groups were identified: “pediatric type, *MYD88*-wildtype” and “adult type, *MYD88*-mutant” (Figure 1). The pediatric type, *MYD88*-wildtype group consisted of 8 patients (5 males, 3 females) with a median age of 14 years (range, 7-25 years). No patients were immunocompromised or HIV positive, and none had a known tumor predisposition syndrome. Two tumors were supratentorial, 1 was infratentorial, and 2 were both supratentorial and infratentorial. Four cases were of the germinal center, and 4 were of the nongerminal center phenotype, according to Hans criteria.¹⁰ All tumors had a non-double-protein expressor phenotype, and none showed a double- or triple-hit genotype for *MYC/BCL2/BCL6*. The median Ki-67 labeling index was 90% (range, 40% to 95%). Genetic alterations commonly occurring in adults with PCNS-LBCL (*MYD88* mutation, *CDKN2A/B* homozygous deletion, HLA gene cluster deletion, and *PRDM1* mutation/deletion) were rare or absent (supplemental Figure 1; supplemental Tables 5-7). Instead, mutations in *GNA13* (50%), *NFKBIE* (50%), and *TP53* (75%) were recurrently identified. Although this group was highly enriched for pediatric age (88%), 25-year-old patient 4 was included based on the lack of *MYD88* mutation and presence of *NFKBIE* and *TP53* mutations. A single tumor in patient 15 showed *GATA2* homozygous deletion,

which has not been reported in systemic or PCNS-LBCL. Interestingly, alterations in *GATA2* are recurrent in pediatric myeloid malignancies such as leukemia and myelodysplastic syndrome.¹¹⁻¹⁴ Other likely oncogenic alterations in individual tumors included focal high-level amplification of *JAK2* and *CD274* (PD-L1) and *EZH2* p.Y646N hotspot mutation that is a recurrent variant found in systemic LBCL and follicular lymphoma. Four tumors in this group exhibited a small number of chromosomal gains or losses (<5 per tumor), whereas the quantity of chromosomal aberrations was high (≥5) in the remaining 4 tumors. No differences in radiologic or histologic features between these pediatric-type PCNS-LBCL and their adult type counterparts was appreciated (Figure 2A-F).

The adult type, *MYD88*-mutant group consisted of 4 young-adult patients (25-38 years of age) and the 6 cases of conventional PCNS-LBCL that occurred in older adults. All tumors harbored activating hotspot missense mutations in *MYD88*. In addition, 80% demonstrated homozygous deletion of *CDKN2A/B*, 60% demonstrated inactivating mutations or deletion of *PRDM1*, 60% demonstrated focal homozygous deletions of the HLA gene cluster on chromosome 6p22.1, and 40% demonstrated *CD79B* mutations. Only single tumors contained *TP53*, *GNA13*, or *NFKBIE* mutations (10% frequency each), in contrast to their frequent occurrence in the pediatric type tumors. Most adult-type, *MYD88*-mutant tumors




Figure 2. Pediatric *MYD88*-wildtype PCNS-LBCL is associated with favorable clinical outcomes compared with its adult-type counterpart. (A-F) Representative radiologic and histopathologic findings in pediatric- and adult-type PCNS-LBCL. Preoperative T1-weighted postcontrast magnetic resonance images of patients with pediatric type, *MYD88*-wildtype (A) or adult type, *MYD88*-mutant (D) PCNS-LBCL, showing overlapping radiologic features, including intraparenchymal mass

(80%) had a high number of chromosomal copy number gains or losses (≥ 5).

A Kaplan-Meier survival analysis demonstrated a 5-year overall survival (OS) of 100% for the pediatric-type, *MYD88* wild-type group, which was substantially longer than PCNS-LBCL in adult patients in previous studies¹⁵⁻²⁰ (Figure 2G; supplemental Tables 8-9). We next performed meta-analysis of clinical outcome data, including 37 additional patients with PCNS-LBCL aged <40 years from 5 published studies,^{2,21-24} along with 5 additional previously unpublished cases. In a total cohort of 53 immunocompetent children and young adults with clinically and pathologically confirmed EBV⁻ PCNS-LBCL, patients aged ≤ 25 years at the time of initial diagnosis had significantly better OS compared with those >25 years of age ($P = .0046$; Figure 2H). The respective 5- and 10-year OS estimates for patients aged ≤ 25 years were 93.8% and 78.8%, which were substantially longer than those for young adults aged 26 to 40 years (62.2% at both intervals) and also older adults from multiple prior large outcome studies.

To our knowledge, this is the first study to interrogate the genomic landscape of EBV-negative PCNS-LBCL in children and adolescents. We discovered a unique pediatric type, *MYD88*-wild-type PCNS-LBCL that correlated with age of onset ≤ 25 years and was genetically defined by enrichment for *TP53*, *NFKBIE*, and *GNA13* mutations, along with an absence of *MYD88* mutation, *CDKN2A/B* homozygous deletion, and HLA gene cluster deletion and a paucity of *CD79B* and *PRDM1* mutations. Young adults between 25 and 40 years of age had genetic profiles similar to those of conventional PCNS-LBCL in older adults. We speculate that these may represent a tumor type that is biologically equivalent to that most commonly occurring in older adults, and we thus collectively termed this group adult type, *MYD88*-mutant. Our findings suggest that unlike adult-type tumors, constitutive activation of the NF- κ B pathway in pediatric-type PCNS-LBCL is driven by *NFKBIE* and *GNA13* mutations instead of *MYD88* hotspot mutations. The effects of the frequent *TP53* mutations are likely to synergize with the prosurvival signals driven by *NFKBIE* and *GNA13* mutations in pediatric-type PCNS-LBCL. The intact HLA alleles in the pediatric-type tumors may be associated with a unique tumor microenvironment and immune status correlating with better overall survival, in contrast with the *MYD88*-mutant tumors in adults that have frequent deletions of the HLA gene cluster associated with immune evasion.^{5,9}

In summary, we have identified a genetically distinct subtype of EBV-negative PCNS-LBCL occurring in immunocompetent pediatric and young-adult patients ≤ 25 years of age. This *MYD88*-wild-type group harboring frequent *TP53*, *NFKBIE*, and *GNA13* mutations has favorable outcomes compared with the *MYD88*-mutant group occurring in older adults >25 years of age. Prospective next-generation DNA sequencing is advocated for PCNS-LBCL in the pediatric and young-adult population, for clinically distinguishing this unique pediatric-type disease.

Figure 2 (continued) lesions with diffuse enhancement and significant edema in the adjacent white matter. Histologic analysis showed sheets of malignant large B-cells diffusely expressing CD20. Hematoxylin and eosin, magnification $\times 400$ (B,E); and CD20, original magnification, $\times 400$ (C,F). (G) Kaplan-Meier survival plot of 7 patients with pediatric type, *MYD88*-wildtype PCNS-LBCL. (H) Kaplan-Meier meta-analysis of 53 pediatric and young-adult patients with PCNS-LBCL stratified by age ≤ 25 years vs 26 to 40 years.

Acknowledgments: The authors thank the staff of the UCSF Clinical Cancer Genomics Laboratory for assistance with genetic profiling.

This study is supported by the Clinical Research Endowment Grant and Rebecca Frankel Award from the University of California San Francisco, Department of Pathology to K.W.W. D.A.S. is supported by the Morgan Adams Foundation and the NIH Director's Early Independence Award (DP5 OD021403). J.L.R. is supported by Leukemia and Lymphoma Society and NIH R01CA139-83-01A1 and R01CA239462 grants. C.-H.G.L. is supported by the UCSF Training Program in Translational Brain Tumor Research, National Institutes of Health (NIH), National Cancer Institute Grant T32CA151022.

Contribution: E.G., C.-H.G.L., D.A.S., and K.W.W. designed the study, performed experiments, and contributed to specimen collection, clinical and pathologic data collection, pathologic review, data analysis, and statistical analysis and wrote the manuscript; D.A.S. and K.W.W. supervised the study; R.S.O. contributed to review of the pathology; R.Z., D.R.B., K.S., G.B.W., S.D., A.B., A.P., and T.T. contributed to specimen collection, data collection, and review of the pathology; Z.Q. and J.Y. performed and evaluated the FISH; J.L.R., L.G.-R., A.A., M.J.B., O.A., A.L.C., J.S.M., and S.K. provided clinical data; M.P. contributed to data collection, pathologic review, and statistical analysis; and all authors had access to clinical, pathologic, and molecular data, critically reviewed the manuscript, and approved its submission.

Conflict-of-interest disclosure: S.K. receives consulting fees from Incyte Corporation and Karyopharm Pharmaceuticals. The remaining authors declare no competing financial interests.

ORCID profiles: E.G., 0000-0002-7050-0831; C.-H.G.L., 0000-0002-8347-9592; Z.Q., 0000-0001-7190-6457; J.Y., 0000-0002-6299-9708; S.D., 0000-0002-5585-0964; J.S.M., 0000-0002-9138-8658; A.P., 0000-0002-8300-7261; T.T., 0000-0003-4551-2555; M.P., 0000-0003-2548-8359; D.A.S., 0000-0003-4571-7999; K.W.W., 0000-0002-8251-902X.

Correspondence: Kwun Wah Wen, Department of Pathology, University of California, San Francisco, 505 Parnassus Ave, M545, Box 0102, San Francisco, CA 94117; e-mail: kwun.wen@ucsf.edu.

References

1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. *Neuro Oncol.* 2020;22(12 suppl 2):iv1-iv96.
2. Attarbaschi A, Abila O, Ronceray L, et al. Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents [published correction appears in *Blood Adv.* 2020;4(6):1012]. *Blood Adv.* 2019;3(24):4291-4297.

3. Dandachi D, Ostrom QT, Chong I, et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. *Cancer Causes Control*. 2019;30(5):477-488.
4. Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma. *Acta Neuropathol*. 2016;131(6):865-875.
5. Mrugala MMRJ, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. *Curr Oncol Rep*. 2009;11(1):73-80.
6. Nayyar N, White MD, Gill CM, et al. *MYD88* L265P mutation and *CDKN2A* loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. *Blood Adv*. 2019;3(3):375-383.
7. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the *MYD88* gene are common in primary central nervous system lymphoma. *Acta Neuropathol*. 2011;122(6):791-792.
8. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. *Blood*. 2000;96(10):3569-3577.
9. Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. *J Pathol*. 2005;206(3):328-336.
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2004;103(1):275-282.
11. Chou ST, Khandros E, Bailey LC, et al. Graded repression of *PU.1/Sfpi1* gene transcription by GATA factors regulates hematopoietic cell fate. *Blood*. 2009;114(5):983-994.
12. Fakhri B, Cashen AF, Duncavage EJ, Watkins MP, Wartman LD, Bartlett NL. Fifty shades of GATA2 mutation: a case of plasmablastic lymphoma, nontuberculous mycobacterial infection, and myelodysplastic syndrome. *Clin Lymphoma Myeloma Leuk*. 2019;19(9):e532-e535.
13. Lentjes MH, Niessen HE, Akiyama Y, de Bruïne AP, Melotte V, van Engeland M. The emerging role of GATA transcription factors in development and disease. *Expert Rev Mol Med*. 2016;18:e3.
14. Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. *Acta Haematol*. 2002;108(4):237-245.
15. Marcus C, Maragkos GA, Alterman RL, Uhlmann E, Pihan G, Varma H. GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas. *J Clin Neurosci*. 2021;83:49-55.
16. Chen Y, Chen H, Chen L, et al. Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma. *Medicine (Baltimore)*. 2019;98(45):e17827.
17. Raoux D, Duband S, Forest F, et al. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. *Neuropathology*. 2010;30(3):232-240.
18. Villa D, Tan KL, Steidl C, et al. Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. *Blood Adv*. 2019;3(23):3953-3961.
19. Takano S, Hattori K, Ishikawa E, et al. MyD88 mutation in elderly predicts poor prognosis in primary central nervous system lymphoma: multi-institutional analysis. *World Neurosurg*. 2018;112:e69-e73.
20. Munch-Petersen HD, Asmar F, Dimopoulos K, et al. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. *Acta Neuropathol Commun*. 2016;4(1):40.
21. Yoon JH, Kang HJ, Kim H, et al. Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience. *J Korean Med Sci*. 2012;27(11):1378-1384.
22. Thorer H, Zimmermann M, Makarova O, et al. Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to non-Hodgkin-Lymphoma Berlin-Frankfurt-Münster protocols for systemic lymphoma. *Haematologica*. 2014;99(11):e238-e241.
23. Ablá O, Sandlund JT, Sung L, et al. A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. *Pediatr Blood Cancer*. 2006;47(7):880-885.
24. Gill KZ, Iwamoto F, Allen A, et al. MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. *PLoS One*. 2014;9(12):e114398.